Diablo Clinical Research
Diablo Clinical Research is an independent Walnut Creek-based clinical trial site founded in 1995 that runs Phase 1-3 drug and device studies for pharma sponsors and CROs across diabetes, vaccines, weight loss, and migraine. The site was acquired by Flourish Research in February 2025 and now operates as Flourish Research - Walnut Creek.
- Company typePrivate
- Founded1995
- HeadquartersWalnut Creek, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Diablo Clinical Research does
Diablo Clinical Research is an independent, single-site clinical research facility founded in 1995 in Walnut Creek, California, that conducts Phase 1 through Phase 3 trials for pharmaceutical and biotechnology sponsors and Contract Research Organizations (CROs). The company operates a 14,300+ square foot facility comprising a 2,300+ sq ft Phase 1 inpatient unit with 2 beds, 6 infusion chairs, and ACLS-certified staff, and a 12,000+ sq ft Phase 2-3 outpatient unit with exam rooms, intake rooms, device study rooms, a DXA room, and an on-site specimen processing lab. Therapeutic areas span Type 1 and Type 2 diabetes (including CGM, artificial pancreas, and insulin delivery device studies), GLP-1 weight loss, vaccines (COVID, RSV, HPV, Flu, CMV, Pneumococcal, Shingles), migraine, celiac disease, cardiovascular, and healthy volunteer studies.
The company's core assets include a database of 18,000+ patients (16,000+ in one source, 18,000+ in another) that is ethnically diverse, an average study retention rate of 98%, and a track record of ranking in the top five highest-enrolling sites in multi-center trials over the last five years. Patient recruitment is run by three full-time specialists using social media, radio, television, direct mail, community outreach, and a Bay Area 6-county catchment of 5.4 million people. Investigator oversight includes a minimum of two on-site investigators at any time, with active participation in site qualification, initiation, and monitoring visits, and ICH-GCP and FDA-compliant regulatory and document management operations, with long-term archival handled via partner Cor-O-Data and confidential destruction via Shred-It.
Commercial operations are B2B and contract-based. Revenue is generated per study from pharmaceutical sponsors (Abbott, Eli Lilly, Pfizer, Novo Nordisk, Sanofi, GSK, Roche, Medtronic, Janssen, AstraZeneca) and CROs (IQVIA, Parexel, ICON, PRA Health Sciences, Syneos Health, Covance) under per-patient and per-protocol arrangements. In February 2025, Diablo Clinical Research LLC was acquired by Flourish Research LLC, expanding Flourish's footprint and infectious-disease capability; the site is now operated as Flourish Research - Walnut Creek, with a stated continuity of operations under the same staff and therapeutic mix.
Diablo Clinical Research firmographics
Firmographics- Name
- Diablo Clinical Research
- Legal name
- Diablo Clinical Research LLC
- Website
- https://diabloclinical.com
- Company type
- Private
- Founded year
- 1995
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Diablo Clinical Research is an independent Walnut Creek-based clinical trial site founded in 1995 that runs Phase 1-3 drug and device studies for pharma sponsors and CROs across diabetes, vaccines, weight loss, and migraine. The site was acquired by Flourish Research in February 2025 and now operates as Flourish Research - Walnut Creek.
- Ownership category
- akta.pro rank
Diablo Clinical Research industry classification
Industry- Product category
- Clinical Research Site Services
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Trial Site Operations & Study Coordination (HLAGACAE)
- akta.pro secondary industries
- Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Clinical CROs (Phase I–IV) (HLAGAAAA)
Keywords
Where Diablo Clinical Research is headquartered
LocationHeadquarters
- HQ city
- Walnut Creek
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Diablo Clinical Research business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Others
Revenue model
- Clinical Trial Services: Contract research services provided to pharmaceutical sponsors and CROs for Phase 1-3 clinical trials. Revenue generated through study contracts based on per-patient enrollment, study complexity, and protocol requirements. Services include patient recruitment, study execution, data collection, and regulatory compliance support.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Per study visit | Clinical trial participation compensation |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
Diablo Clinical Research product offering
Product offeringCore offering
Diablo Clinical Research is an independent, single-site clinical research facility that conducts Phase 1 through Phase 3 clinical trials for pharmaceutical sponsors and Contract Research Organizations (CROs). The company operates a 14,300+ sq ft facility with separate inpatient (Phase 1) and outpatient (Phase 2-3) units, providing patient recruitment, study execution, clinical data collection, and regulatory compliance support across multiple therapeutic areas including diabetes, weight loss, vaccines, migraine, celiac disease, and medical devices. Participants receive study-related care and medications at no cost in exchange for time and travel compensation.
Product overview
Diablo Clinical Research operates as an independent, single-site clinical research facility established in 1995, offering Phase 1-3 clinical trial services for both medications and medical devices. The company conducts trials across multiple therapeutic areas including diabetes (Type 1, Type 2, and device studies), weight loss (GLP-1 medications), vaccines (COVID, Flu, HPV, RSV, and others), migraine, celiac disease, and cardiovascular disease. The facility spans 14,000 square feet with separate inpatient (Phase 1) and outpatient (Phases 2-3) units. Key service offerings include specialized device studies for diabetes monitoring technology, healthy volunteer studies, and a robust patient recruitment platform serving a 5.4 million population base in the Bay Area with 16,000+ subject database.
Differentiator
Problem solved
Functional benefit
Products and services
- Celiac Disease Studies Clinical trials for celiac disease, a genetic autoimmune condition in which gluten damages the small intestine, enrolling patients diagnosed for at least 6 months and on a gluten-free diet for 6 consecutive months.
- Diabetes Device Studies Clinical studies focused on innovative diabetes devices including Blood Glucose Meters (BGM), Continuous Glucose Monitoring (CGM), Artificial Pancreas (AP), Insulin Delivery Systems, and non-invasive blood glucose monitoring devices.
- General Device Studies Medical device clinical trials covering therapeutic, diagnostic, and other device categories, optionally including healthy volunteers as comparison populations alongside target-condition subjects.
- Healthy Volunteer Studies Clinical trials enrolling healthy volunteers who contribute data and serve as comparison populations for studies targeting specific medical conditions.
- Migraine Studies Clinical trials testing new and approved medications for treating and preventing migraines, which involve severe recurring neurological symptoms including throbbing head pain, visual disturbances, nausea, and sensitivity to light and sound.
- Type 2 Diabetes Studies Clinical trials for Type 2 diabetes focusing on blood sugar control, diabetic neuropathy pain relief, kidney disease, high blood pressure, and metabolic syndrome.
- Type 1 Diabetes Studies Clinical trials for Type 1 diabetes including studies of new and approved therapies and research on the latest glucose monitoring devices, including continuous glucose monitoring and artificial pancreas studies for patients ages 8 and older.
- Vaccine Studies Vaccine clinical trials covering COVID, COVID/RSV, CMV, HPV, Pneumococcal, RSV, Flu, eCOLI/Flu, Celiac, and Shingles vaccines, conducted with healthy volunteer populations.
- Weight Loss Studies Weight loss clinical trials investigating diets, exercise, behavioral interventions, medications, and surgical procedures, with current studies focusing on Glucagon Like Peptide (GLP-1) medications.
- Patient Recruitment Services Patient recruitment and enrollment services for current clinical studies across multiple therapeutic areas, supported by 3 full-time recruitment specialists, an ethnically diverse database of 16,000+ subjects, and multi-channel recruitment including social media, digital advertising, radio, TV, direct mail, community outreach, on-site seminars, and health fairs.
- Phase 1 Inpatient Unit Facility Services Dedicated 2,300+ sq ft full-service Phase 1 inpatient unit with 2 beds, 6 infusion chairs, ACLS-certified staff, overnight and extended-stay capability, dedicated monitor workspace with T1 internet, and secure parking for sponsor-initiated Phase 1 trials.
- Phase 2-3 Outpatient Unit Facility Services Dedicated 12,000+ sq ft Phase 2-3 outpatient facility with 3 exam rooms, 6 intake rooms, dedicated device study rooms, DXA room, temperature-controlled drug storage, and on-site specimen processing lab.
Quantifiable outcome
- Top 5 highest enrolling sites in multi-center trials over the last five years
- +3 more outcomes
Companies that use Diablo Clinical Research
Customer profileNamed customers12 records
Segments3 records
Ideal customer profiles2 records
Diablo Clinical Research technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Diablo Clinical Research partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered core and minor.
- Flourish Research LLCcoreFlourish Research LLC acquired Diablo Clinical Research LLC in February 2025. Following the acquisition, Diablo Clinical Research became part of the Flourish Research Network and is now known as Flourish Research - Walnut Creek. The acquisition was intended to expand Flourish Research's geographic and therapeutic scope in the infectious disease clinical trials sector.
- Abbott Laboratories (Abbott Diabetes Care, Abbott Point of Care)coreLong-standing sponsor partner conducting diabetes-related clinical trials including glucose monitoring devices and diabetes treatments
- Eli LillycorePharmaceutical sponsor partner for metabolic and diabetes clinical trials
- PfizercorePharmaceutical sponsor conducting clinical trials across multiple therapeutic areas
- Novo NordiskcorePharmaceutical sponsor for diabetes and weight loss clinical trials including GLP-1 medications
- SanoficorePharmaceutical sponsor for diabetes and vaccine clinical trials
- GlaxoSmithKline (GSK)corePharmaceutical sponsor for vaccine and general pharmaceutical clinical trials
- Roche DiagnosticscoreDiagnostic company sponsor for diabetes monitoring and diagnostic device studies
- MedtroniccoreMedical device sponsor for diabetes technology and insulin delivery system studies
- JanssencorePharmaceutical sponsor for clinical trials across therapeutic areas
- AstraZenecacorePharmaceutical sponsor for cardiovascular, diabetes, and other therapeutic area trials
- IQVIAcoreMajor CRO partner managing clinical trials on behalf of pharmaceutical sponsors
- ParexelcoreLeading CRO partner for clinical trial management and execution
- ICONcoreGlobal CRO partner for clinical research services
- PRA Health SciencescoreCRO partner for clinical trial management
- Syneos HealthcoreIntegrated CRO partner for clinical and commercial solutions
- CovancecoreDrug development services CRO partner
- Cor-O-DataminorOffsite long-term document storage provider with 24-hour document retrieval capability
- Shred-ItminorSecure document destruction service for confidential clinical trial documentation
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Diablo Clinical Research competitors and assessment
Company assessmentMarket position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Diablo Clinical Research social profiles
Digital presenceDiablo Clinical Research compliance and trust
Trust signalCompliance2 records
Diablo Clinical Research financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diablo Clinical Research leadership team
Management profileNumber of profiles
Diablo Clinical Research funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diablo Clinical Research M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diablo Clinical Research
What does Diablo Clinical Research do?
Diablo Clinical Research is an independent, single-site clinical research facility that conducts Phase 1 through Phase 3 clinical trials for pharmaceutical sponsors and Contract Research Organizations (CROs). The company operates a 14,300+ sq ft facility with separate inpatient (Phase 1) and outpatient (Phase 2-3) units, providing patient recruitment, study execution, clinical data collection, and regulatory compliance support across multiple therapeutic areas including diabetes, weight loss, vaccines, migraine, celiac disease, and medical devices. Participants receive study-related care and medications at no cost in exchange for time and travel compensation.
Is Diablo Clinical Research a public or private company?
Diablo Clinical Research is a private company. It is classified as corporate owned and is currently acquired.
When was Diablo Clinical Research founded?
Diablo Clinical Research was founded in 1995. It employs 11 to 50 people.
Where is Diablo Clinical Research based?
Diablo Clinical Research is headquartered in Walnut Creek, United States, in the North America region.
How does Diablo Clinical Research make money?
One revenue line is on record: clinical Trial Services.
Does Diablo Clinical Research have an API?
No public API is recorded for Diablo Clinical Research.
What industry is Diablo Clinical Research in?
Diablo Clinical Research's product category is Clinical Research Site Services. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination, with a secondary code of HLAGAAAI, Patient Recruitment, Site Feasibility & Trial Enablement CROs. Its NAICS code is 5417 and its SIC code is 8731.